1. Antiviral and immunomodulatory effects of ouabain against congenital Zika syndrome model.
- Author
-
Carvalho DCM, Dunn T, Campos RK, Tierney JA, Onyoni F, Cavalcante-Silva LHA, Pena LJ, Rodrigues-Mascarenhas S, Wu P, and Weaver SC
- Subjects
- Animals, Mice, Humans, Female, Pregnancy, Neural Stem Cells drug effects, Neural Stem Cells virology, Neural Stem Cells metabolism, Placenta metabolism, Placenta virology, Immunomodulating Agents pharmacology, Immunologic Factors pharmacology, Immunologic Factors therapeutic use, Immunomodulation drug effects, Ouabain pharmacology, Zika Virus Infection immunology, Zika Virus Infection drug therapy, Zika Virus Infection virology, Disease Models, Animal, Zika Virus drug effects, Antiviral Agents pharmacology, Antiviral Agents therapeutic use
- Abstract
Zika virus (ZIKV) is an arbovirus associated with neurological disorders accompanying congenital infections. With no vaccine or antiviral approved, there is an urgent need for the development of effective antiviral agents against ZIKV infection. We evaluated the anti-ZIKV and immunomodulatory activity of ouabain, a Na
+ /K+ -ATPase inhibitor known to have immunomodulatory and antiviral activities, using human neural stem and progenitor cells (hNS/PCs) and a murine model of congenital Zika syndrome (CZS). Our data demonstrated that ouabain reduces ZIKV infection in hNS/PCs, mouse placenta, yolk sac, and the fetal head. Ouabain mitigated neurogenesis impairment triggered by ZIKV in hNS/PCs and prevented ZIKV-mediated reduction of fetus and head sizes. In addition, ouabain decreased tumor necrosis factor and interleukin-1β levels in the placenta, highlighting its immunomodulatory activity in the murine model. Our findings indicate that ouabain possesses anti-ZIKV and immunomodulatory activities, suggesting that it should be investigated further as a promising treatment for CZS., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2025
- Full Text
- View/download PDF